News | January 25, 2025
Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr
Q3 FY25 revenue up 24% to Rs 3,230 crore
Q3 FY25 revenue up 24% to Rs 3,230 crore
Alankit will undertake the verification of pending e-KYC enrollments through the Beneficiary Identification System (BIS) platform provided by the National Health Authority (NHA).
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Subscribe To Our Newsletter & Stay Updated
